TG4010 + nivolumab + chemotherapy

TG4010 + nivolumab + chemotherapy is an investigational combination regimen studied primarily in advanced non-small cell lung cancer (NSCLC). **TG4010** is a therapeutic cancer vaccine using a recombinant Modified Vaccinia Ankara (MVA) viral vector engineered to express the tumor-associated antigen MUC1 and interleukin-2 (IL-2). **Nivolumab** is a monoclonal antibody immunotherapy that blocks the immune checkpoint programmed death-1 (PD-1), enhancing T-cell responses against tumors. **Chemotherapy** in these studies usually refers to standard first-line regimens, most often platinum-based doublet therapy such as cisplatin/gemcitabine or cisplatin/vinorelbine. This multi-modal approach aims to both stimulate an anti-tumor immune response (via the vaccine), remove immune inhibition (via checkpoint inhibition), and directly cytotoxically target tumor cells (via chemotherapy). Mechanistically, TG4010 induces an immune response specifically targeting **MUC1**-expressing tumor cells, while IL-2 in the vaccine enhances immune cell proliferation. Nivolumab further relieves immune suppression by blocking PD-1 on T cells, and chemotherapy provides cytotoxic reduction of tumor burden and may increase tumor antigen release. Preclinical and clinical studies have established the rationale for this combination, with Phase 2 studies demonstrating safety and potential efficacy, especially in patient subgroups with specific immune biomarkers (e.g., low triple positive activated lymphocytes, TrPAL). As of the search cutoff, a Phase 2 trial investigating TG4010 + nivolumab + chemotherapy in NSCLC is ongoing, and FDA IND approval has been granted for study in this setting[1][4][5][6].

Other names

Opdivo + TG4010 + chemotherapyTG4010 cancer vaccine + nivolumab + chemotherapy